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A B S T R A C T
Background: We investigated prevalence and predictive factors for ESBL-E carriage in a population of mostly
travellers prior to their travel (n = 2216). In addition, we examined ESBL genotype before travel and compared
these to returning travellers.
Method: A questionnaire and faecal sample were collected before travel, and a second faecal sample was col-
lected immediately after travel. Faecal samples were analysed for ESBL-E, with genotypic characterization by
PCR and sequencing. Risk factors for ESBL-E carriage prior to travel were identified by logistic regression
analyses.
Results: Before travel, 136 participants (6.1%) were colonized with ESBL-E. Antibiotic use in the past three
months (ORadjusted 2.57; 95% CI 1.59–4.16) and travel outside of Europe in the past year (1.92, 1.28–2.87) were
risk factors for ESBL-E colonisation prior to travel. Travel outside of Europe carried the largest attributable risk
(39.8%). Prior to travel 31.3% (40/128) of participants carried blaCTX-M 15 and 21.9% (28/128) blaCTX-M 14/
18. In returning travellers 633 acquired ESBL-E of who 53.4% (338/633) acquired blaCTX-M 15 and 17.7%
(112/633) blaCTX-M 14/18.
Conclusion: In our population of Dutch travellers we found a pre-travel ESBL-E prevalence of 6.1%. Prior to
travel, previous antibiotic use and travel outside of Europe were the strongest independent predictors for ESBL-E
carriage, with travel outside of Europe carrying the largest attributable risk. Our molecular results suggest ESBL
genes found in our study population prior to travel were in large part travel related.
1. Introduction
The prevalence of antimicrobial resistance in the community has
increased to significant levels in many countries, even in those with
historically prudent use of antibiotics [1,2]. Globally, ESBL-E pre-
valence varies from 2 to 46% between communities from different sub-
https://doi.org/10.1016/j.tmaid.2019.101547
Received 26 August 2019; Received in revised form 30 November 2019; Accepted 16 December 2019
∗ Corresponding author. Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015, GD
Rotterdam, the Netherlands.
E-mail address: m.arcilla@erasmusmc.nl (M.S. Arcilla).
1 both authors contributed equally.
Travel Medicine and Infectious Disease xxx (xxxx) xxxx
1477-8939/ © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Please cite this article as: Maris S. Arcilla, et al., Travel Medicine and Infectious Disease, https://doi.org/10.1016/j.tmaid.2019.101547
regions [3]. Every year ESBL-E carriage rates increase worldwide with
more than 5% among healthy individuals [2,3]. Also in Europe, an
increase in ESBL-E community carriage rates has been documented over
the past years [4]. Three previous studies found an ESBL-E prevalence
of 4.5–8.6% among healthy Dutch individuals [5–7]. Two of these
identified travel to Asia or Africa in the previous 12 months and the use
of proton pump inhibitors (PPI's) to be associated with a higher risk for
ESBL-E carriage in the community. Other risk factors were the use of
antimicrobials, travel to North and Latin America, keeping cows, living
in the proximity of a mink farm, and owning or having contact with a
horse [5–7]. In countries with similar ESBL-E community carriage rates
as the Netherlands, previous antibiotic use was identified as a predictor
in Japan, Germany and France [3,8–10]. Travel to Asia or Africa and
travel to Africa or Greece were identified as predictors for ESBL-E
carriage in Swedish and German communities, respectively [9,11].
Overall, studies found a variety of risk factors. Therefore, elucida-
tion of risk factors is needed to identify definitive sources for ESBL-E
carriage in the community and to foresee possible public health risks
and interventions. In this paper, we report on the prevalence of and risk
factors for ESBL-E carriage in a large convenience cohort of travellers
living in the community in the Netherlands prior to their planned in-
tercontinental travel. In addition, we compared genotypes and re-
sistance profiles of ESBL-E isolated before and after intercontinental
travel.
2. Methods
2.1. Study design and participants
To determine risk factors for ESBL-E carriage in the community we
used a population of 2001 travellers and 215 household members of
those travellers who were enrolled in the COMBAT-study, a multicenter
longitudinal cohort study on the risk of ESBL-E acquisition during in-
ternational travel [12]. Participants were included from November
2012 until November 2013. All participants had provided a faeces
sample, collected by rectal swab (Fecal Swab with transport medium;
Copan, Brescia, Italy), and a questionnaire 1–3 weeks before travel.
Thus, the results of this baseline culture and the accompanying
metadata reflect, to some extent, the endemic level and potential de-
terminants of ESBL-E carriage in the Dutch general population. Fig. 1
depicts a flowchart of the study design used to answer the research
questions of this paper.
2.2. Procedures
Rectal swabs were incubated in tryptic soy broth supplemented with
vancomycin (50 mg/L). After overnight culture, the broth was sub-
cultured onto chromID ESBL agar plates (bioMerieux, Marcy l’Etoile,
France). After overnight incubation, all morphologically distinct co-
lonies were identified to the species level using a matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry (Bruker
Microflex LT, Bruker, London, UK). For all Enterobacteriaceae anti-
biotic minimum inhibitory concentrations were measured with the
automated susceptibility testing system Vitek 2 (bioMerieux).
Phenotypical confirmation of ESBL production was performed by
combination disc diffusion tests, according to current national Dutch
guidelines [13]. The presence of ESBL genes was confirmed by PCR
using primers specific for CTX-M enzyme groups 1, 2, 8, 9, and 25.
Sequence confirmation was performed to further characterize the most
prevalent and largest CTX-M groups, 1 and 9 [12].
2.3. Statistical analysis
Predictors for ESBL-E carriage prior to travel were determined by
multivariable logistic regression models that were constructed ac-
cording the method proposed by Bursac and colleagues [14] and ana-
lysed with IBM SPSS Statistics (version 21.0). Data from pre-travel
questionnaires were used to determine potential risk factors for ESBL-E
carriage and included demographics, pre-existing morbidity and med-
ication use, food consumption, travel history, hospital admissions and
antibiotic use during the past three months. Results are presented as
odds ratios (ORs) and 95% confidence intervals (CI95). The ORs were
used for calculating the population attributable risk (PAR), i.e. the
proportion of participants that would not be ESBL carriers if the risk
factor was eliminated.
Differences in co-resistance/multidrug resistance between ESBL-
Fig. 1. Flow chart of study design.
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E.coli isolated from participants prior to travel and acquired ESBL-E. coli
isolates in returning travellers were determined using chi square tests.
In case a traveller had more than one ESBL-producing E. coli, only the
first isolate was included in the analysis. Multidrug resistance was de-
fined as E. coli non-susceptible to one or more agent(s) in three or more
antimicrobial classes [15]. To determine differences in genotype in
ESBL-producing E. coli from travellers who acquired these during travel
to different subregions according to the United Nations geoscheme
[12], we used multivariable logistic regression models.
3. Results
3.1. Risk factors for ESBL-E colonisation prior to travel
2001 travellers and 215 non-travelling household members were
included in the original COMBAT-study. From the complete study po-
pulation 136 participants (122 travellers and 14 non-travelling house-
hold members) were found to carry ESBL-E prior to travel (Fig. 1).
Antibiotic use in the past three months was the strongest in-
dependent predictor for ESBL-E colonisation prior to travel (adjusted
OR 2.57, CI95 1.59–4.16 (Table 1, Supplementary Table A1). To assess
effects of different antibiotic classes in the model, we exchanged the
variable antibiotic use during the past three months (no vs yes) for a
variable indicating antibiotic class (no antibiotics; beta-lactam; quino-
lone; or other antibiotics). In this analysis, beta-lactam use was most
strongly associated with ESBL-E colonisation (ORadjusted 4.07, CI95
2.00–8.28). Quinolone use (ORadjusted 1.88, 0.41–8.69) was not statis-
tically significantly associated with ESBL-E colonisation
(Supplementary Table A1). 14.9% of ESBL-E carriage prior to travel
could be attributed to antibiotic use in the past three months (Table 2).
Travel outside of Europe in the past year was also associated with
ESBL-E colonisation prior to travel (ORadjusted 1.92, CI95 1.28–2.87)
(Supplementary Table A1). The PAR was 39.8% for travel outside of
Europe. In more detail, we detected associations between ESBL-E co-
lonisation prior to travel and previous travel to Africa (ORadjusted 2.19,
CI95 1.36–3.52), Asia (ORadjusted 1.58, CI95 1.04–2.39) and Oceania
(ORadjusted 3.63, CI95 1.59–8.29) in the past year (Table 1). To assess
effects of different subregions in the model, we exchanged the variable
indicating the continent (Africa, Asia or Oceania) with a variable in-
dicating the different subregions according to the United Nations
Geoscheme. By this classification, travel to Northern Africa (ORadjusted
3.76, CI95 2.15–6.55), Eastern Asia (ORadjusted 3.16, CI95 1.31–7.58),
and Australia and New Zealand (ORadjusted 3.73, CI95 1.63–8.54) in the
past year were associated with ESBL-E colonisation prior to travel
(Supplementary Table A1). Participants working in healthcare with
daily patient contact tended to be associated with an increased risk for
Table 1
Predictors for ESBL-E carriage for travellers and non-travelling household members prior to travel in the final adjusted logistic regression model.
Number of travellers
prior to travel
Number of travellers with ESBL
colonisation prior to travel
Travellers with ESBL
colonisation prior to travel (%)
OR adjusted (95%
CI)
p
Type of participant
Traveller 2001 122 6.1
Non-travelling household member 215 14 6.5 1.11 (0.60–2.04) 0.75
Education level
No education, elementary school or pre-
vocational secondary education†
290 11 3.8
Vocational secondary education 323 16 5.0 1.66 (0.68–4.01) 0.26
Senior general secondary education or pre-
university education
249 22 8.8 3.14 (1.34–7.35) 0.01
Higher professional education 704 49 7.0 2.38 (1.09–5.19) 0.03
Academic education 642 37 5.8 1.76 (0.78–3.96) 0.17
Antibiotic use the past three months
No† 1989 108 5.4
Yes 222 27 12.2 2.57 (1.59–4.16) <0.001
Chronic disease
No† 1700 111 6.5
Yes 488 21 4.3 0.60 (0.36–1.01) 0.053
Daily patient contact
(No) profession in healthcare without daily
patient contact†
1819 102 5.6
Medical or other profession in healthcare
with daily patient contact
366 30 8.2 1.49 (0.95–2.33) 0.08
Frequency of travel in past twelve months
No trip 207 14 6.8
1 or 2 trip(s) 923 45 4.9 0.53 (0.27–1.03) 0.06
3 or 4 trips 671 50 7.5 0.69 (0.35–1.38) 0.29
5 or more trips 362 24 6.6 0.63 (0.29–1.37) 0.25
Travel to Asia
No† 1753 93 5.3
Yes 463 43 9.3 1.58 (1.04–2.39) 0.03
Travel to Africa
No† 1960 109 5.6
Yes 256 27 10.5 2.19 (1.36–3.52) 0.001
Travel to Oceania
No† 2174 128 5.9
Yes 42 8 19.0 3.63 (1.59–8.29) 0.002
† reference category
Table 2
Population-attributable risk (PAR) of predictors for ESBL-E carriage
prior to travel.
predictor PAR
Antibiotic use the past three months 14.9%
Travel outside of Europe 39.8%
Travel to Asia 13.2%
Travel to Africa 13.4%
Travel to Oceania 4.8%
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ESBL-E carriage prior to travel (ORadjusted 1.49, CI95 0.95–2.33). Other
variables including pre-existent chronic bowel disease, diarrhoea,
dietary variables, and use of antacids were not associated with ESBL-E
colonisation prior to travel.
3.2. Comparison of ESBL-E genotypes in study population prior to travel to
study population returning from travel
Before travel, 136 participants were colonized with ESBL-E, from
which 164 morphologically different strains were isolated. Of travellers
that were negative for ESBL-E prior to travel, 633 travellers acquired
ESBL-E during travel, from which 859 morphologically different strains
were isolated [12].
In both the study population prior to travel and the population re-
turning from travel, CTX-M group 1 was the most prevalent ESBL group,
being found in respectively 71/131 (54.2%) and 428/692 (61.8%) of
isolates in ESBL-E colonized participants. The second most prevalent
ESBL group was CTX-M group 9, that was detected in 49/131 (37.4%)
and 209/692 (30.2%) of isolates in participants, respectively (Fig. 2a
and b). Prior to travel, 40 of 128 participants carried blaCTX-M-15
(31.3%), 28 blaCTX-M-14/18 (21.9%), 14 blaCTX-M-1 (10.9%) and 11
blaCTX-M-27 (8.6%) (Fig. 3a). In the study population returning from
travel 338 of 633 travellers (53.4%) acquired blaCTX-M-15, 112
blaCTX-M- 14/18 (17.7%), 70 blaCTX-M-27 (11.1%) and 52 blaCTX-M-
55/57 (8.2%) (Fig. 3b).
Among participants that acquired ESBL-E during travel, prevalence
of ESBL groups and ESBL genes differed per subregion (Supplementary
Figure A1 and A2). Multivariable logistic regression models showed
travellers to Middle- and Eastern Africa (ORadjusted 2.6, CI95 1.2–5.5),
Northern Africa (ORadjusted 2.7, CI95 1.1–6.9), Western Africa (ORadjusted
7.5, CI95 1.6–35.0) and Southern Asia (ORadjusted 9.5, CI95 4.3–20.7)
were at increased risk for CTX-M group 1 acquisition when compared to
travellers who did not visit these subregions. More specifically, tra-
vellers to Western Africa (ORadjusted 9.6, CI95 2.1–44.5), Southern Asia
(ORadjusted 9.3, CI95 4.4–19.3) and Western Asia (ORadjusted 11.7, CI95
1.4–95.8) were at increased risk for acquisition of ESBL gene CTX-M-15.
Furthermore, travellers to Central- and Eastern Asia were at increased
risk for acquisition of CTX-M group 9 (ORadjusted 3.3, CI95 1.4–7.5) and
ESBL-gene CTX-M-14/18 (ORadjusted 3.5, CI95 1.5–7.9) compared to
travellers who did not visit this subregion (data not shown).
3.3. Comparison of co-resistance in study population prior to travel to study
population returning from travel
Prior to travel 120 participants carried at least one ESBL-producing
E. coli, with a total of 150 morphologically different E. coli strains. 585
returning travellers acquired at least one ESBL-producing E. coli with a
total of 759 morphologically different E. coli strains. Co-resistance to
gentamicin (p < 0.001), nitrofurantoin (p = 0.02), trimethoprim-
sulfamethoxazole (p < 0.001) and multidrug resistance (p = 0.004)
were significantly more prevalent among ESBL-E isolated from parti-
cipants returning from travel compared to those isolated from partici-
pants before travel (Table 3).
4. Discussion
The ESBL-E carriage rate of 6.1% observed among this cohort of
Dutch individuals prior to travel was slightly higher (versus 4.5% and
5.1%) and lower (versus 8.6%) compared to previous Dutch studies
among healthy individuals [5–7] and is slightly higher than the overall
carriage rate of 4% measured in healthy individuals in Northern Europe
[3]. The two major determinants for ESBL-E carriage prior to travel,
antibiotic use and travel outside of Europe, reinforce previous findings
[5–7]. The most prevalent ESBL genes, both prior to travel and re-
turning from travel, were blaCTX-M-15 and blaCTX-M-14/18.
Our large study population made it possible to study risk factors for
pre-travel carriage in 136 participants. Although previous antibiotic
use, in particular beta-lactam antibiotics, was the strongest independent
predictor for ESBL-E carriage prior to travel, only 14.9% of ESBL-E
carriage could be attributed to antibiotic use prior to travel. Quinolone
use was the antibiotic class most strongly associated with ESBL-E ac-
quisition during travel [12], but was not significantly associated with
ESBL-E carriage prior to travel, possibly because of a lack of power.
Kantele et al. demonstrated that the use of fluoroquinolones during
54%38%
8%
Prior to travel
CTX-M group 1 (n=71)
CTX-M group 9 (n=49)
Other CTX-M group or
TEM/SHV ESBL (n=11)
Fig. 2a. Distribution of ESBL groups prior to travel (T0) (n = 128 travellers and household members).
*Only unique ESBL genes per participant were included in the pie diagram. If a participant carried two of the same ESBL genes, the ESBL gene was only included once
in this pie diagram.
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travel selected for ESBL-E acquisition during travel [16].
Travel outside of Europe in the past 12 months was another strong
independent predictor for ESBL-E carriage prior to travel, and carried
the largest attributable risk (39.8% versus 14.9% for antibiotic use).
Particularly, those who travelled to Eastern Asia, Northern Africa and
Australia or New Zealand were at increased risk for ESBL-E carriage
prior to travel. This is in line with other studies, which report travel to
Asia or Africa as an important predictor for ESBL-E carriage in the
community [6,7,9,11]. In addition to previous travel to Asia or Africa,
Reuland et al. found travel to the United States of America to be a risk
factor for ESBL-E carriage in the community [6], which was not con-
firmed in our study. Interestingly, in our study previous travel to
Australia and/or New Zealand was a newly discovered predictor for
community ESBL-E carriage, even after correcting for travel duration
(data not shown). There were 41 participants who had previously tra-
velled to Australia and/or New Zealand, of which 8 (19.5%), who all
had travelled to Australia, carried ESBL-E prior to travel. So far, no data
has been published on the prevalence of ESBL-E carriage in Australian
communities and traveller studies typically lack data on ESBL-E ac-
quisition during travel in Australia. However, a high ESBL-E rate of
18% has been reported in long-term care facilities in Australia and an
ESBL-E rate of 12% among E. coli hospital isolates [17,18]. The role of
possible sources for ESBL-E carriage in the Australian community de-
serves clarification.
62%
30%
8%
A er travel
CTX-M group 1 (n=428)
CTX-M group 9 (n=209)
Other CTX-M group or
TEM/SHV ESBL (n=55)
Fig. 2b. Distribution of ESBL groups after travel (T1) (n = 633 travellers with ESBL acquisition).
*Only unique ESBL genes per participant were included in the pie diagram If a traveller acquired two of the same ESBL genes, the ESBL gene was only included once
in this pie diagram.
31%
21%
8%
3%
5%
11%
5%
16%
Prior to travel
CTX-M-15 (n=40) CTX-M 14/18 (n=28) CTX-M-27 (n=11) CTX-M-55/57 (n=4)
SHV-12 (n=7) CTX-M-1 (n=14) CTX-M-3 (n=7) Other (n=21)
Fig. 3a. Distribution of unique ESBL genes (n = 131) prior to travel (T0) (n = 128 travellers and household members).
*Other: CTX-M 32 (n = 2), CTX-M group 1 not specified (n = 4), CTX-M 24/65 (n = 2), CTX-M 9 (n = 1),CTX-M group 9 not specified (n = 7),TEM-52 (n = 3),
SHV-2 (n = 2).
†ESBL-E isolates from 8 travellers were excluded from the pie diagram due to failure to determine the specific gene at baseline (T0).
‡ With the primers used no distinction could be made between CTX-M 15/28/94/167, CTX-M 14/17/18, CTX-M 1/61/138, CTX-M 3/22/162 and CTX-M 55/79/164.
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In agreement with other studies, no association between consump-
tion of food products including chicken meat and ESBL-E carriage prior
to travel was found. There has been debate whether food items are an
important source of ESBL-producing E. coli in humans. It has been
suggested successful ESBL-carrying plasmids facilitate transmission
between different reservoirs, however a recent study failed to demon-
strate a close link between ESBL-carrying plasmid types from people in
the general population and livestock or food-associated reservoirs
[19,20]. We also did not find an association between use of antacids
and ESBL-E carriage prior to travel. This conflicting finding with pre-
vious research may be explained by that we did not make a distinction
between use of PPI's and neutralizing antacids. Therefore it could be
that our participants were mostly using neutralizing antacids, which
have not been associated with ESBL-E carriage yet, as opposed to PPI's
[6,7,21].
In line with the worldwide epidemiology of ESBL genotypes, we
found returning travellers from Western Africa, Southern Asia and
Western Asia to be at increased risk for blaCTX-M-15 acquisition and
returning travellers from Central- and Eastern Asia to be at increased
risk for blaCTX-M-14/18 acquisition [2,22]. Our study did not have the
statistical power to test the association between pre-travel carriage of
blaCTX-M-15 or blaCTX-M-14/18 and previous travel to blaCTX-M-15
or blaCTX-M-14 endemic regions. However, as blaCTX-M-14/18 is not
prevalent in the Netherlands [6,7,23,24], these genes found prior to
travel could very well be acquired during previous travels by our par-
ticipants. The proportion of blaCTX-M-14/18 of 21% in ESBL genes in
our population prior to travel is higher or comparable to other Dutch
studies, which found a proportion of blaCTX-M-14 of 13–19% in the
community [6,7,23].
Significantly more gentamicin, nitrofurantoin, trimethoprim-sulfa-
methoxazole and multidrug resistant E. coli isolates were carried by
participants returning from travel than before travel. A possible ex-
planation could be a relatively rapid loss of genes encoding for co-re-
sistances in ESBL-E over time [25,26]. The persistence of carriage of
ESBL-E seems not to be a random process as a recent study demon-
strated certain strain/gene combinations were more prevalent in pro-
longed carriers in the community [27]. More studies are needed to
identify whether strain, plasmid or gene related factors are responsible
for persistence of ESBL-E carriage and to delineate the dynamics of
resistance gene acquisition and loss.
A limitation of our study was that the PAR in our study cannot be
fully extrapolated to the general adult population in the Netherlands, as
participants were recruited from travel clinics, they were more likely to
travel internationally and had the financial means to do so.
5. Conclusion
International travel is a major risk factor for ESBL-E carriage in the
Dutch population and may - directly or indirectly - be a substantial if
not dominant contributor to the endemic level of ESBL-E carriage in the
Dutch general population. With current predictions of further growth in
international travel, we envision that travel will constitute an important
driving force for ESBL-E carriage in the community of countries like the
Netherlands, that are otherwise relatively prudent regarding their an-
tibiotic usage.
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49%
16%
10%
8%
4%
2%
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A er travel
CTX-M-15 (n=338) CTX-M 14/18 (n=112) CTX-M-27 (n=70) CTX-M-55/57 (n=52)
SHV-12 (n=27) CTX-M-1 (n=16) CTX-M-3 (n=12) Other (n=65)
Fig. 3b. Distribution of unique ESBL genes (n = 692) after travel (T1) (n = 633 travellers with ESBL acquisition).
*Other: CTX-M-14-like (n = 10), CTX-M group 8 (n = 9), CTX-M-65 (n = 8), CTX-M-32 (n = 7), CTX-M group 2 (n = 7), CTX-M-24b (n = 6), TEM-52c (n = 4),
SHV-2a (n = 3), CTX-M-24 (n = 2), TEM-176 (n = 2), CTX-M-15 like (n = 2), CTX-M-38 (n = 1), SHV-2 (n = 1), SHV-28 (n = 1), VEB (n = 1), CTX-M group 1 not
specified (n = 1).
Table 3
Co-resistance rates among ESBL-E. coli strains isolated from study population
prior to travel versus those isolated directly after travel.
antibiotic Co-resistance
prior to travel
Co-resistance
returning from
travel
pc
(n = 120
participantsa)
(n = 585
participantsa)
imipenem 0 (0.0%) 2 (0.3%) 0.521
meropenem 0 (0.0%) 1 (0.2%) 0.650
gentamicin 18 (15.0%) 180 (30.8%) < 0.001
nitrofurantoin 1 (0.8%) 35 (6.0%) 0.020
trimethoprim-
sulfamethoxazole
56 (46.7%) 377 (64.4%) < 0.001
ciprofloxacin 43 (35.8%) 262 (44.8%) 0.071
colistin 0 (0.0%) 8 (1.4%) 0.198
multidrug resistanceb 36 (30.0%) 259 (44.3%) 0.004
a Co-resistance was determined for participants with ESBL-positive E. coli
isolates only. In case a participant carried/acquired more than one E. coli iso-
late, co-resistance was only determined for the first E. coli isolate.
b Multidrug resistance to gentamicin, trimethoprim-sulfamethoxazole, ci-
profloxacin.
c p-value determined using chi-square tests.
M.S. Arcilla, et al. Travel Medicine and Infectious Disease xxx (xxxx) xxxx
6
JMvH, PJJvG, HAV, JP and DCM drafted the Article with help from all
authors. All authors read and approved the final version of the paper.
Funding
This work was supported by the Netherlands Organisation for
Health Research and Development (ZonMw).
Declaration of competing interest
We declare no competing interests.
Acknowledgments
This work was supported by Netherlands Organisation for Health
Research and Development (ZonMw, grant number 205200003). We
thank all the employees of the Travel Clinics (Institute for Tropical
Diseases, Havenziekenhuis; Centre of Tropical Medicine and Travel
Medicine, Academic Medical Centre; EASE Travel Health & Support) for
their help in the recruitment of participants.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tmaid.2019.101547.
References
[1] de Greeff SC, Mouton JW. Consumption of antimicrobial agents and antimicrobial
resistance among medically important bacteria in The Netherlands in 2017.
Nethmap; 2018.
[2] Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M beta-lactamases:
temporal and geographical shifts in genotype. J Antimicrob Chemother
2017;72(8):2145–55.
[3] Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization
with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk
factors among healthy individuals: a systematic review and metaanalysis. Clin Infect
Dis : Off Publ Infect Dis Soc Am 2016;63(3):310–8.
[4] Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of
extended-spectrum beta-lactamases in the community: toward the globalization of
CTX-M. Clin Microbiol Rev 2013;26(4):744–58.
[5] Huijbers PM, de Kraker M, Graat EA, van Hoek AH, van Santen MG, de Jong MC,
et al. Prevalence of extended-spectrum beta-lactamase-producing
Enterobacteriaceae in humans living in municipalities with high and low broiler
density. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis
2013;19(6):E256–9.
[6] Reuland EA, Al Naiemi N, Kaiser AM, Heck M, Kluytmans JA, Savelkoul PH, et al.
Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in
Amsterdam. J Antimicrob Chemother 2016;71(4):1076–82.
[7] Wielders CCH, van Hoek A, Hengeveld PD, Veenman C, Dierikx CM, Zomer TP, et al.
Extended-spectrum beta-lactamase- and pAmpC-producing Enterobacteriaceae
among the general population in a livestock-dense area. Clin Microbiol Infect : Off
Publ Eur Soc Clin Microbiol Infect Dis 2017;23(2). 120.e1-.e8.
[8] Luvsansharav UO, Hirai I, Niki M, Nakata A, Yoshinaga A, Moriyama T, et al.
Prevalence of fecal carriage of extended-spectrum beta-lactamase-producing
Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother: Off J
Jpn Soc Chemother 2011;17(5):722–5.
[9] Meyer E, Gastmeier P, Kola A, Schwab F. Pet animals and foreign travel are risk
factors for colonisation with extended-spectrum beta-lactamase-producing
Escherichia coli. Infection 2012;40(6):685–7.
[10] Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, Bertrand X, Thomas-Jean F,
Bert F, et al. 10-Fold increase (2006-11) in the rate of healthy subjects with ex-
tended-spectrum beta-lactamase-producing Escherichia coli faecal carriage in a
Parisian check-up centre. J Antimicrob Chemother 2013;68(3):562–8.
[11] Ny S, Lofmark S, Borjesson S, Englund S, Ringman M, Bergstrom J, et al.
Community carriage of ESBL-producing Escherichia coli is associated with strains of
low pathogenicity: a Swedish nationwide study. J Antimicrob Chemother
2017;72(2):582–8.
[12] Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MCJ, van Genderen PJJ,
Goorhuis A, et al. Import and spread of extended-spectrum beta-lactamase-produ-
cing Enterobacteriaceae by international travellers (COMBAT study): a prospective,
multicentre cohort study. Lancet Infect Dis 2017;17(1):78–85.
[13] Bernards ATBM, Stuart JC, et al. NVMM guideline: laboratory detection of highly
resistant microorganisms, version 2.0. Leeuwarden: Netherlands Society for
Medical Microbiology; 2012.
[14] Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in
logistic regression. Source Code Biol Med 2008;3:17.
[15] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an
international expert proposal for interim standard definitions for acquired re-
sistance. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis
2012;18(3):268–81.
[16] Kantele A, Mero S, Kirveskari J, Laaveri T. Fluoroquinolone antibiotic users select
fluoroquinolone-resistant ESBL-producing Enterobacteriaceae (ESBL-PE) - data of a
prospective traveller study. Trav Med Infect Dis 2017;16:23–30.
[17] Lim CJ, Cheng AC, Kennon J, Spelman D, Hale D, Melican G, et al. Prevalence of
multidrug-resistant organisms and risk factors for carriage in long-term care facil-
ities: a nested case-control study. J Antimicrob Chemother 2014;69(7):1972–80.
[18] Mendes RE, Mendoza M, Banga Singh KK, Castanheira M, Bell JM, Turnidge JD,
et al. Regional resistance surveillance program results for 12 Asia-Pacific nations
(2011). Antimicrob Agents Chemother 2013;57(11):5721–6.
[19] de Been M, Lanza VF, de Toro M, Scharringa J, Dohmen W, Du Y, et al.
Dissemination of cephalosporin resistance genes between Escherichia coli strains
from farm animals and humans by specific plasmid lineages. PLoS Genet
2014;10(12):e1004776.
[20] Dorado-Garcia A, Smid JH, van Pelt W, Bonten MJM, Fluit AC, van den Bunt G,
et al. Molecular relatedness of ESBL/AmpC-producing Escherichia coli from hu-
mans, animals, food and the environment: a pooled analysis. J Antimicrob
Chemother 2018;73(2):339–47.
[21] Huizinga P, van den Bergh MK, van Rijen M, Willemsen I, van 't Veer N, Kluytmans
J. Proton pump inhibitor use is associated with extended-spectrum beta-lactamase-
producing Enterobacteriaceae rectal carriage at hospital admission: a cross-sec-
tional study. Clin Infect Dis: Off Publ Infect Dis Soc Am 2017;64(3):361–3.
[22] Canton R, Gonzalez-Alba JM, Galan JC. CTX-M enzymes: origin and diffusion. Front
Microbiol 2012;3:110.
[23] van Hoek AH, Schouls L, van Santen MG, Florijn A, de Greeff SC, van Duijkeren E.
Molecular characteristics of extended-spectrum cephalosporin-resistant
Enterobacteriaceae from humans in the community. PLoS One
2015;10(6):e0129085.
[24] Voets GM, Platteel TN, Fluit AC, Scharringa J, Schapendonk CM, Stuart JC, et al.
Population distribution of Beta-lactamase conferring resistance to third-generation
cephalosporins in human clinical Enterobacteriaceae in The Netherlands. PLoS One
2012;7(12):e52102.
[25] Ochman H, Lawrence JG, Groisman EA. Lateral gene transfer and the nature of
bacterial innovation. Nature 2000;405(6784):299–304.
[26] Lanza VF, de Toro M, Garcillan-Barcia MP, Mora A, Blanco J, Coque TM, et al.
Plasmid flux in Escherichia coli ST131 sublineages, analyzed by plasmid con-
stellation network (PLACNET), a new method for plasmid reconstruction from
whole genome sequences. PLoS Genet 2014;10(12):e1004766.
[27] van Duijkeren E, Wielders CCH, Dierikx CM, van Hoek A, Hengeveld P, Veenman C,
et al. Long-term carriage of extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella pneumoniae in the general population in The
Netherlands. Clin Infect Dis: Off Publ Infect Dis Soc Am 2018;66(9):1368–76.
M.S. Arcilla, et al. Travel Medicine and Infectious Disease xxx (xxxx) xxxx
7
